Ribomic Inc (4591):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Ribomic Inc (4591) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9326
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Ribomic Inc (Ribomic), a subsidiary of Otsuka Pharmaceutical Co Ltd, is a biopharmaceutical venture company. The company develops molecular targeted pharmaceutical drugs using RNA aptamers. Its technology includes RiboART system a platform technology to treat therapeutic aptamers. Ribomic’s pipeline products include RBM001, RBM002, RBM003, RBM004, RBM005, RBM006, RBM007, RBM008 and RBM101. The company’s products are used to treat pain, sepsis, lung fibrosis and other organ fibrosis, bone diseases, and eye diseases and inflammatory disorders. It has collaboration with other pharmaceutical companies for research and development activities. Ribomic is headquartered in Tokyo, Japan.

Ribomic Inc (4591) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Ribomic Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ribomic Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ribomic Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ribomic Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Ribomic Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Ribomic Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Ribomic Enters into Agreement with Seikagaku 10
Ribomic Enters into Research Agreement with Astellas Pharma 11
Ribomic Enters into Research Agreement with Evec 12
Ribomic Extends Research Agreement with Otsuka Pharma 13
Licensing Agreements 14
Otsuka Pharma to Enter into Licensing Agreement with Ribomic for RBM001 14
Fujimoto Pharma Enters into Licensing Agreement with Ribomic 15
Equity Offering 16
Ribomic Raises USD26 Million in IPO of Shares 16
Ribomic Inc – Key Competitors 18
Ribomic Inc – Key Employees 19
Ribomic Inc – Locations And Subsidiaries 20
Head Office 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
Ribomic Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Ribomic Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ribomic Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ribomic Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ribomic Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Ribomic Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Ribomic Enters into Agreement with Seikagaku 10
Ribomic Enters into Research Agreement with Astellas Pharma 11
Ribomic Enters into Research Agreement with Evec 12
Ribomic Extends Research Agreement with Otsuka Pharma 13
Otsuka Pharma to Enter into Licensing Agreement with Ribomic for RBM001 14
Fujimoto Pharma Enters into Licensing Agreement with Ribomic 15
Ribomic Raises USD26 Million in IPO of Shares 16
Ribomic Inc, Key Competitors 18
Ribomic Inc, Key Employees 19

List of Figures
Ribomic Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ribomic Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ribomic Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ribomic Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ribomic Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Ribomic Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ribomic Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Ribomic Inc (4591):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Epic Sciences Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Epic Sciences Inc (Epic Sciences) focuses to develop novel diagnostics for personalized treatment of cancer. The company develops AR-V7 test to identify and molecularly characterize circulating tumor cells in a blood sample. It also offers biopharma solutions such as resistance to AR signali …
  • Alabama Municipal Electric Authority:企業の戦略的SWOT分析
    Alabama Municipal Electric Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • SoftBank Group Corp:企業の戦略・SWOT・財務分析
    SoftBank Group Corp - Strategy, SWOT and Corporate Finance Report Summary SoftBank Group Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Lunaphore Technologies SA:医療機器:M&Aディール及び事業提携情報
    Summary Lunaphore Technologies SA (Lunaphore) is a medical device company that develops tissue processing solutions for inmmunohistochemistry. The company builds tumor analysis and classification platforms based on a microfluidic technologies. It offers FFeX, a fast fluidic exchange technology that …
  • Pentair plc (PNR)-石油・ガス分野:企業M&A・提携分析
    Summary Pentair plc (Pentair) is an industrial manufacturing company. It designs, manufactures and markets water system products and solutions for filtration, separation and fluid process management; and products that guard sensitive electrical and electronic equipment; and heat management solutions …
  • Noble Energy Inc (NBL):石油・ガス:M&Aディール及び事業提携情報
    Summary Noble Energy Inc (Noble) is an independent energy company that explores for and produces crude oil, natural gas and natural gas liquids (NGLs). The company’s portfolio includes both US unconventional and global offshore conventional assets. Noble has operations in the Denver-Julesburg (DJ) B …
  • Karus Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Karus Therapeutics Ltd (Karus) is a drug development company that designs and develops cancer therapies. The company offers small molecule drugs with immunotherapy for the treatment of hematological and solid tumors. Its pipeline products include KA2507 and KA2237 inhibitors. Karus’ KA2507 i …
  • Global Ports Holding PLC (GPH):企業の財務・戦略的SWOT分析
    Global Ports Holding PLC (GPH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Banco Pan SA (BPAN4):企業の財務・戦略的SWOT分析
    Banco Pan SA (BPAN4) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • SonarMed Inc:医療機器:M&Aディール及び事業提携情報
    Summary SonarMed Inc (SonarMed) is a medical device company that develops endotrachael systems used for the inhalation and ventilation assistance patients. The company offers products such as artificial respiratory, endotrachael tubes, biomedical acoustics, SonarMed Airwave, medical devices, disposa …
  • Inter Pipeline Ltd (IPL):企業の財務・戦略的SWOT分析
    Inter Pipeline Ltd (IPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Arconic Inc (ARNC):企業の財務・戦略的SWOT分析
    Arconic Inc (ARNC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Orient Europharma Co Ltd (4120):企業の財務・戦略的SWOT分析
    Summary Orient Europharma Co Ltd (OEP) is a pharmaceutical company that manufactures and markets prescription medication, Innovative medical and Infant health products. The company’s prescription medication products include cardiovascular medication, immunology medicine, metabolism medicine, neurolo …
  • University of California Berkeley-製薬・医療分野:企業M&A・提携分析
    Summary University of California Berkeley (UC Berkeley), a subsidiary of University of California is an educational university that offers educational programs and research services. The university’s academic programs comprise law and economics program, legal studies; lesbian, gay, bisexual, and tra …
  • Hunter Douglas NV (HDG):企業の財務・戦略的SWOT分析
    Hunter Douglas NV (HDG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Praxair Inc (PX):石油・ガス:M&Aディール及び事業提携情報
    Summary Praxair Inc (Praxair) is a producer and supplier of industrial gases. The company produces atmospheric gases including oxygen, nitrogen, argon and rare gases, and process gases such as carbon dioxide, helium, hydrogen, electronic gases, specialty gases and acetylene. It also designs and buil …
  • Mattress Firm Holding Corp.:企業のM&A・事業提携・投資動向
    Mattress Firm Holding Corp. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mattress Firm Holding Corp. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • BioTime Inc (BTX):製薬・医療:M&Aディール及び事業提携情報
    Summary BioTime Inc (BioTime) is a biotechnology company which focuses on regenerative medicine and plasma volume expanders. The company’s Hextend is a blood plasma volume expander used for the treatment of hypovolemia in surgery, emergency trauma treatment, and other applications. It is also develo …
  • Korea Western Power Co Ltd-エネルギー分野:企業M&A・提携分析
    Summary Korea Western Power Co., Ltd. (KOWEPO), a subsidiary of Korea Electric Power Corporation (KEPCO), develops electricity resources, and generates and supplies electricity. The company’s power generation portfolio includes Taen, Pyeongtaek, Seoincheon, and Gunsan power complexes consisting of t …
  • PeptiDream Inc (4587):企業の財務・戦略的SWOT分析
    Summary PeptiDream Inc (PeptiDream) operates as a biopharmaceutical company. It discovers and develops peptides, peptide-drug, small molecule based, and conjugate therapeutics to address unmet medical needs. The company provides a proprietary peptide discovery platform system (PDPS), a versatile dis …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆